Preoperative factors predicting poor therapeutic efficacy of holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia.

OBJECTIVES: We assessed preoperative factors predicting the poor therapeutic efficacy of holmium laser enucleation of the prostate (HoLEP) in benign prostatic hyperplasia (BPH) patients. METHODS: The present study included 159 patients who underwent HoLEP between August 2015 and June 2021 at our institution. Overall therapeutic efficacy was divided into good and poor therapeutic efficacies according to changes in the international prostate symptom score (IPSS), IPSS quality of life (IPSS-QOL), and the maximum urinary flow rate. Patients were divided into good and poor therapeutic efficacy groups based on findings obtained 3 months after HoLEP, and comparative assessments were performed between the two groups. RESULTS: The therapeutic efficacy of HoLEP was poor in 53 (33.3%) out of 159 patients. Intravesical prostatic protrusion (IPP), IPSS, IPSS-QOL, post-void residual volume (PVR), and the presence of overactive bladder (OAB) were significantly higher in the poor therapeutic efficacy group than in the good therapeutic efficacy group. A multivariable analysis of several factors identified the preoperative presence of OAB and short IPP as independent risk factors for the poor therapeutic efficacy of HoLEP. When treatment efficacy was divided according to risk factors, poor therapeutic efficacy was observed in only 14% of patients with prolonged IPP and the absence of OAB. CONCLUSIONS: The therapeutic efficacy of HoLEP may be poor in patients with OAB and short IPP, resulting in the significant deterioration of lower urinary tract symptoms. Accordingly, it is important to consider the presence or absence of OAB and IPP measurements when selecting indications for HoLEP.

Development of a Complete En-Bloc Technique with Direct Bladder Neck Incision: A Newly Modified Approach for Holmium Laser Enucleation of the Prostate.

Introduction: The objectives of this study were to introduce a newly developed approach for holmium laser enucleation of the prostate (HoLEP) called the "complete en-bloc technique," and to compare the clinical outcomes of this approach with those of previously performed procedures. Methods: This study retrospectively assessed the perioperative findings from 548 patients with benign prostatic hyperplasia (BPH) undergoing HoLEP who were divided into the following groups according to the consecutive changes in surgical techniques: group A (n = 236), the three-lobe technique; group B (n = 137), the conventional en-bloc technique; and group C (n = 175), the complete en-bloc technique with direct bladder neck incision. Results: There were no significant differences in major clinical characteristics or urinary symptoms among groups A, B, and C. Although there was no significant difference in the resected prostate weight among the three groups, the enucleation time was significantly shorter and total laser energy was significantly lower in group C than in groups A and B. Therefore, the enucleation efficiency, calculated by dividing the resected prostate weight by the enucleation time, was significantly greater in group C than in groups A and B. Furthermore, no significant differences in the postoperative urinary symptoms, including the International Prostate Symptom Score (IPSS), quality of life, maximum flow rate, postvoid residual, and persistent stress urinary incontinence rate, were noted among the three groups, and there were no significant differences in the incidences of major perioperative complications, including the blood transfusion, bladder injury, urethral stricture, and bladder neck sclerosis among the three groups. Conclusions: These findings suggest that our complete en-bloc technique can improve the clinical outcomes of HoLEP in BPH patients, even in difficult cases, considering its markedly improved enucleation efficiency.

Arteriosclerosis related factors had no clinical significant correlation with resistive index in symptomatic benign prostatic hyperplasia.

OBJECTIVE: To investigate whether the resistive index (RI) in symptomatic benign prostatic hyperplasia (BPH) could be used as a surrogate index of the severity of lower urinary tract symptoms (LUTS) due to BPH, and whether arteriosclerosis-related factors were associated with the RI in LUTS due to BPH. METHODS: From January 2005 to April 2008, a total of 625 men with LUTS due to BPH were prospectively enrolled. Patients with heart failure, liver cirrhosis, prostatic cancer, neurogenic bladder, acute prostatitis, acute urinary retention, urethral stenosis, history of transurethral resection or any drug treatment for BPH, or currently under drug treatment for type 2 diabetes mellitus or dyslipidemia were excluded. Variables analyzed included estimated smoking status, blood pressure, body mass index (BMI), serum fasting glucose (FBS), lipid profile (low-density lipoprotein-cholesterol, high density lipoprotein-cholesterol and triglyceride), serum prostate-specific antigen, International Prostatic Symptom Score (IPSS), quality of life score, maximum urinary flow rate (Q(max.)), and postvoid residual urine volume (PVR). We also measured total prostate volume, transition zone (TZ) index, and RI using transrectal ultrasonography. Correlations among parameters were statistically examined. RESULTS: RI was significantly correlated with IPSS, Q(max.), and PVR, but not with blood pressure, BMI, or FBS. On multiple regression analysis, RI was a significant independent variable of IPSS, TZ index, and PVR. CONCLUSIONS: These findings suggest that RI might represent a surrogate index of the severity of LUTS due to BPH, and that RI might have no clinically significant relationship with arteriosclerosis-related factors.

Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia.

OBJECTIVES: To examine the usefulness of several parameters obtained by transrectal ultrasonography in predicting acute urinary retention (AUR). METHODS: The present study consecutively enrolled 1962 men with a complaint of lower urinary tract symptoms. Of these men, 245 were found to have AUR on examination at our clinic. We assessed the International Prostate Symptom Score (IPSS), maximal urinary flow rate, and postvoid residual urine volume and measured the total prostate volume, transition zone index (TZI), and resistive index (RI) using transrectal ultrasonography. To compare the usefulness of these indexes for predicting AUR, we calculated the area under the receiver operating characteristic curve for each index and for age. RESULTS: In patients without AUR, age, prostate-specific antigen level, IPSS, maximal urinary flow rate, and postvoid residual urine volume were significantly correlated with both the TZI and the RI (P < .001). Multiple regression analysis demonstrated that age, maximal urinary flow rate, postvoid residual urine volume, and TZI were significant independent determinants of the RI (P < .001). Patients with AUR were, on average, older and had an elevated prostate-specific antigen level, increased IPSS, and greater TZI and RI than patients without AUR (P < .001). The area under the receiver operating characteristic curve was 0.640 (95% confidence interval [CI] 0.618-0.662) for age, 0.674 (95% CI 0.653-0.695) for prostate-specific antigen level, 0.787 (95% CI 0.768-0.805) for total prostate volume, 0.821 (95% CI 0.803-0.838) for IPSS, 0.860 (95% CI 0.844-0.875) for TZI, and 0.867 (95% CI 0.851-0.882) for RI. CONCLUSIONS: The RI and TZI obtained using transrectal ultrasonography correlated with the incidence of AUR and are useful predictors of AUR in patients with benign prostatic hyperplasia.